Earnings summaries and quarterly performance for REVVITY.
Executive leadership at REVVITY.
Prahlad Singh
Detailed
President and Chief Executive Officer
CEO
AG
Anita Gonzales
Detailed
Vice President and Chief Accounting Officer
JG
Joel Goldberg
Detailed
Senior Vice President, Administration, General Counsel and Secretary
MK
Maxwell Krakowiak
Detailed
Senior Vice President and Chief Financial Officer
MV
Miriame Victor
Detailed
Senior Vice President and Chief Commercial Officer
TV
Tajinder Vohra
Detailed
Senior Vice President, Global Operations
Board of directors at REVVITY.
AM
Alexis Michas
Detailed
Non-Executive Chair
FW
Frank Witney
Detailed
Director
MK
Michael Klobuchar
Detailed
Director
MV
Michel Vounatsos
Detailed
Director
MM
Michelle McMurry-Heath
Detailed
Director
PW
Pascale Witz
Detailed
Director
PB
Peter Barrett
Detailed
Director
SC
Samuel Chapin
Detailed
Director
SV
Sophie Vandebroek
Detailed
Director
Research analysts who have asked questions during REVVITY earnings calls.
Vijay Kumar
Evercore ISI
7 questions for RVTY
Also covers: A, ABT, AVTR +23 more
Luke Sergott
Barclays
6 questions for RVTY
Also covers: A, AVTR, BRKR +20 more
Patrick Donnelly
Citi
5 questions for RVTY
Also covers: A, AVTR, BIO +24 more
Andrew Cooper
Raymond James
4 questions for RVTY
Also covers: AZTA, CDNA, CTKB +12 more
Catherine Schulte
Baird
4 questions for RVTY
Also covers: A, CSTL, EXAS +8 more
Dan Arias
Stifel Financial Corp.
4 questions for RVTY
Also covers: A, BLLN, GH +11 more
Daniel Brennan
TD Cowen
4 questions for RVTY
Also covers: A, ADPT, AVTR +25 more
DL
Dan Leonard
UBS Group AG
4 questions for RVTY
Also covers: A, AVTR, BIO +13 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for RVTY
Also covers: A, ALGN, AVTR +29 more
PS
Puneet Souda
Leerink Partners
4 questions for RVTY
Also covers: A, ABCL, BRKR +21 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
3 questions for RVTY
Also covers: A, ADPT, AVTR +21 more
Tycho Peterson
Jefferies
3 questions for RVTY
Also covers: A, AVTR, BIO +22 more
BC
Brandon Couillard
Wells Fargo
2 questions for RVTY
Also covers: A, AVTR, BLLN +4 more
DB
Dan Brennan
UBS
2 questions for RVTY
Also covers: A, ADPT, AVTR +17 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
2 questions for RVTY
Also covers: A, AVTR, CDXS +15 more
DL
Daniel Leonard
Stifel Financial Corp.
2 questions for RVTY
Also covers: A, AVTR, BIO +15 more
Doug Schenkel
Wolfe Research LLC
2 questions for RVTY
Also covers: A, AVTR, BRKR +19 more
JW
Josh Waldman
Cleveland Research
2 questions for RVTY
Also covers: MTD
Brandon Couillard
Wells Fargo & Company
1 question for RVTY
Also covers: A, AVTR, BIO +10 more
CR
Catherine Ramsey
BTIG
1 question for RVTY
Also covers: A, EXAS, MTD
Douglas Schenkel
Wolfe Research, LLC
1 question for RVTY
Also covers: A, AVTR, BRKR +21 more
Jack Meehan
Nephron Research LLC
1 question for RVTY
Also covers: A, AVTR, BIO +18 more
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for RVTY
Also covers: A, AKYA, AVTR +11 more
Subbu Nambi
Guggenheim Securities
1 question for RVTY
Also covers: ADPT, BLLN, BOLD +23 more
TP
Tycho Pedersen
Jefferies
1 question for RVTY
Recent press releases and 8-K filings for RVTY.
Revvity provides 2026 guidance and AI-driven growth outlook
RVTY
Guidance Update
Product Launch
Share Buyback
- Revvity reported solid Q4 execution and reiterated 2–3% organic growth guidance for 2026, underpinned by cost measures enacted in Q4 2025 to drive outsized margin expansion in 2026 and early 2027.
- The Revvity Signals software platform is positioned as a net beneficiary of AI; three major product launches—Synthetica, BioDesign, and Labgistics—are slated by early 2027 to help double the business within five years.
- In immunodiagnostics, ex-China performance remained strong, with U.S. revenue share rising from 5% to 20% post-acquisition and an objective to double U.S. market penetration, while China diagnostics is conservatively expected to decline mid-20s% in 2026.
- Capital allocation priorities include opportunistic share buybacks—12% of shares repurchased since 2023—servicing a €500 million bond due July, and pursuing bolt-on M&A to fill strategic portfolio gaps.
2 days ago
Revvity provides 2026 outlook and strategic roadmap
RVTY
Guidance Update
Product Launch
Share Buyback
- Prahlad Singh reiterated 2–3% organic growth guidance for 2026, with cost-saving measures driving margin expansion to 28% by year-end and further gains in early 2027.
- Life Science Solutions saw reagent revenues return to growth in Q4, while instrument order trends are improving; the business is expected to move from low-single-digit declines to modest growth as platforms drive consumable pull-through.
- Diagnostics outperformed on reproductive health and newborn screening, with ex-China immunodiagnostics strong; U.S. immunodiagnostics now represents 20% of sales and is targeted to double, while China diagnostics is conservatively forecast down mid-20% in 2026.
- Revvity Signals is positioned as a net AI beneficiary, with upcoming launches of Synthetica, BioDesign and Logistics aimed at doubling the platform’s revenue over five years.
- Capital allocation remains opportunistic: 12% of shares repurchased since 2023, a €500 million bond due July to be refinanced, and focus on bolt-on M&A after deploying ~$10 billion in strategic transactions.
2 days ago
Revvity outlines 2026 guidance and strategic priorities at TD Cowen Conference
RVTY
Guidance Update
Product Launch
Share Buyback
- At the TD Cowen conference, Revvity reaffirmed 2026 organic growth guidance of 2–3%, assuming pharma-biotech market stability, and outlined cost measures driving outsized margin expansion in H2 2026 and into H1 2027.
- Life Science Solutions: reagent sales have grown in four of the last five quarters despite market weakness, while instrument demand is expected to shift from negative to positive low single-digit growth as installed platforms drive consumable pull-through.
- Software: Revvity Signals is positioned as a regulated AI-ready platform; upcoming NPIs—BioDesign, Synthetica (full launch by late 2026/early 2027), and Labgistics—are key to the goal of doubling Signals revenue over the next five years.
- Immunodiagnostics ex-China posted strong growth; the U.S. now represents ~20% of immunodiagnostics revenues (vs. 5% at acquisition), with plans to double share and expand into esoteric autoimmune testing.
- Capital allocation: Revvity repurchased 12% of shares (~15 million) since 2023, will repay a €500 million bond in July, and remains opportunistic on bolt-on M&A.
2 days ago
Revvity outlines 2026 strategy and financial outlook at Raymond James conference
RVTY
Guidance Update
Product Launch
New Projects/Investments
- Revvity is a $3 billion company split 50% between life sciences and diagnostics, with 85% of revenue recurring.
- Management highlighted four innovation pillars: major software NPIs (Xynthetica, BioDesign, Signals LabGistics), integrated life sciences/diagnostics workflows, a growing GMP reagents pipeline, and U.S. immunodiagnostics expansion.
- 2026 guidance calls for 2–3% organic growth on ~$3 billion revenue, an adjusted operating margin of 28% (up ~100 bps), and high single-digit EPS growth.
- Operational excellence initiatives have driven 90% free cash flow conversion, repurchased 10% of shares since launch, and target 100 bps margin expansion in 2026 with further gains in 2027.
- AI is viewed as a net tailwind for both software (via Xynthetica) and reagents, expected to accelerate discovery and create a wet-lab validation bottleneck.
4 days ago
Revvity presents 2026 guidance and strategic priorities
RVTY
Guidance Update
Share Buyback
Product Launch
- Portfolio split: Revvity is a $3 billion business, equally weighted between life sciences and diagnostics, with ~85% recurring revenue and a long‐range organic growth target of 6%–8%.
- 2026 guidance: Revenue of ~$3 billion, 2%–3% organic growth, and an 28% adjusted operating margin (≈100 bps expansion), driving high single-digit EPS growth.
- Four growth pillars: 1) Software innovation (Xynthetica launched Q4 2025; BioDesign and Signals LabGistics due H2 2026), 2) integrated life sciences/diagnostics partnerships (e.g., Sanofi T1D, Genomics England), 3) GMP reagents pipeline acceleration, and 4) U.S. immunodiagnostics expansion toward a 40% market share.
- Operational excellence: Achieved ~90% free cash flow conversion (vs. 70% pre-Revvity), repurchased nearly 10% of shares since 2023, and plans ~100 bps margin expansion in 2026 via headcount, supply chain, and footprint synergies.
4 days ago
Revvity outlines transformation, growth pillars and 2026 guidance at Raymond James conference
RVTY
Guidance Update
- Revvity reported a $3 billion portfolio split 50% life sciences/50% diagnostics with 85% recurring revenue, following its March 2023 launch and analytical business divestiture.
- Management highlighted four growth pillars: software innovation (Xynthetica, BioDesign, Signals LabGistics), integrated life sciences-diagnostics partnerships (e.g., Sanofi T1D, Genomics England), GMP reagents capacity build-out and US immunodiagnostics expansion.
- For 2026, Revvity targets $3 billion revenue, 2–3% organic growth, 28% adjusted operating margin and high-single-digit EPS growth.
- Plans include ~100 bps margin expansion in 2026 and further 2027 leverage via productivity initiatives (headcount optimization, supply chain synergies, footprint consolidation).
4 days ago
Revvity reports Q4 2025 results
RVTY
Earnings
Guidance Update
Share Buyback
- Revvity beat Q4 expectations with $1.70 adjusted EPS (FY $5.06, +3% YoY)
- Q4 organic revenue growth of 4% (7% diagnostics, flat life sciences); FY organic growth 3%
- Q4 adjusted operating margin 29.7%; generated $162 M free cash flow (84% conversion), FY $515 M FCF (87% conversion); net debt/EBITDA 2.7×
- Repurchased $800 M of shares in 2025 (over $1.5 B since mid-2023), reducing share count by 8.5 M
- Acquired ACD/Labs adding $20 M revenue (~75 bps growth); 2026 guidance: 2–3% organic growth, revenue $2.96–$2.99 B, adjusted EPS $5.35–$5.45, margin 28%
Feb 2, 2026, 1:00 PM
Revvity reports Q4 2025 results and 2026 outlook
RVTY
Earnings
Guidance Update
Share Buyback
- Revenue of $772 million in Q4 2025 (+4% organic), driven by 7% diagnostic growth and flat life sciences
- Q4 adjusted EPS of $1.70, boosting full-year adjusted EPS to $5.06 alongside 3% organic full-year growth on $2.86 billion revenue
- Reiterated 2026 organic growth guidance of 2–3%, with expected revenue of $2.96 billion–$2.99 billion and adjusted EPS of $5.35–$5.45
- Repurchased >$800 million of shares in 2025 (including $168 million in Q4), reducing share count by 8.5 million; total buybacks since mid-2023 exceed $1.5 billion
- Closed ACD/Labs acquisition, expected to add ~$20 million in 2026 revenue (+75 bps growth) ; introduced AI platform Signals Synthetica to accelerate drug R&D workflows
Feb 2, 2026, 1:00 PM
Revvity reports Q4 2025 results and issues 2026 guidance
RVTY
Earnings
Guidance Update
- Revvity delivered Q4 2025 revenue of $772 M (+6% y/y), adjusted operating margin of 29.7%, EPS of $1.70 (+20% y/y) and free cash flow of $162 M.
- For FY 2025, revenue was $2.856 B (+4% y/y), adjusted operating margin 27.1%, EPS $5.06 (+3% y/y) and free cash flow $515 M.
- Diagnostics led segment growth, with immunodiagnostics organic revenue up +7% y/y and reproductive health posting mid-single-digit growth, though margins were pressured by tariffs and FX.
- 2026 guidance calls for revenue of $2.968–2.99 B (+4–5%), adjusted operating margin ~28% and EPS of $5.35–5.45.
Feb 2, 2026, 1:00 PM
Revvity announces Q4 2025 results
RVTY
Earnings
Guidance Update
Share Buyback
- Revvity delivered Q4 revenue of $772 million (+4% organic) and adjusted EPS of $1.70, exceeding guidance; for the full year, organic growth was 3% and adjusted EPS was $5.06.
- Diagnostics segment organic growth was 7% in Q4, led by reproductive health and immunodiagnostics, while life sciences organic growth was flat.
- The company reiterated 2026 guidance of 2–3% organic growth, revenue of $2.96 billion–$2.99 billion, and adjusted EPS of $5.35–$5.45 with a 28% operating margin target.
- In 2025, Revvity repurchased over $800 million of shares (8.5 million shares), bringing total buybacks since mid-2023 to $1.5 billion (15 million shares).
- Completed the acquisition of ACD/Labs in mid-January (adding ~$20 million revenue) and launched the AI platform Signals Synthetica to enhance its software offerings.
Feb 2, 2026, 1:00 PM
Quarterly earnings call transcripts for REVVITY.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more